GHAPPcast

FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications

2:36

Thank you to AbbVie for their support on this FAQ Video Module.

In this FAQ video module, Brooke Hodnick, PA-C, breaks down key updates to the expanded upadacitinib label for adults with moderate to severe ulcerative colitis and Crohn’s disease, effective October 10, 2025. The discussion focuses on what qualifies as an “approved systemic therapy” in the context of patients who have had an…